Effect of omega-3 fatty acids on cardiovascular events in high-risk patients with hypertriglyceridemia in Japan: a 3-year post-marketing surveillance study (OCEAN3 survey)

BACKGROUND Studies on the efficacy of prescription omega-3 polyunsaturated fatty acids to reduce cardiovascular events have produced conflicting results. RESEARCH DESIGN AND METHODS This 3-year prospective post-marketing surveillance study evaluated the effect of omega-3-acid ethyl esters (O3AEE; usual dosage 2 g/day) on cardiovascular events in high-risk statin-treated Japanese patients with hypertriglyceridemia. Statin-treated patients not receiving O3AEE were included as a reference cohort. The composite primary endpoint was cardiovascular death, myocardial infarction, stroke, angina requiring coronary revascularization, or peripheral arterial disease requiring surgery or peripheral arterial intervention. RESULTS At 3 years, Kaplan-Meier estimated cumulative incidence of the primary endpoint was 2.5% (95% confidence interval, 2.1%-2.9%) in O3AEE-treated patients (N = 6,580) and 2.7% (2.4%-3.1%) in non-O3AEE-treated patients (N = 7,784; hazard ratio, 0.99; 95% confidence interval, 0.79-1.23). Incidence of heart failure requiring hospitalization was 0.4% with O3AEE versus 0.8% in non-O3AEE-treated patients (hazard ratio, 0.47; 95% confidence interval, 0.28-0.78; P<0.05). CONCLUSIONS Among patients receiving statins, cardiovascular event incidence did not differ significantly between O3AEE-treated patients and non-O3AEE-treated patients. Further studies are required before definitive conclusions can be drawn on the effect of O3AEE on cardiovascular event incidence in high-risk patients with hypertriglyceridemia. TRIAL REGISTRATION ClinicalTrials.gov, NCT02285166.

[1]  D. Mozaffarian,et al.  Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk: A Secondary Analysis of the STRENGTH Trial. , 2021, JAMA cardiology.

[2]  Yutang Wang.  Omega-3 Fatty Acids Effect on Major Cardiovascular Events in Patients at High Cardiovascular Risk. , 2021, JAMA.

[3]  Hwan-Sik Hwang,et al.  Omega-3 Fatty Acids Effect on Major Cardiovascular Events in Patients at High Cardiovascular Risk. , 2021, JAMA.

[4]  M. Chung,et al.  Omega-3 Fatty Acids Effect on Major Cardiovascular Events in Patients at High Cardiovascular Risk. , 2021, JAMA.

[5]  J. Manson,et al.  Effect of Marine Omega-3 Fatty Acid and Vitamin D Supplementation on Incident Atrial Fibrillation: A Randomized Clinical Trial. , 2021, JAMA.

[6]  C. Sirtori,et al.  Lipid Lowering Drugs: Present Status and Future Developments , 2021, Current Atherosclerosis Reports.

[7]  J. Manson,et al.  Marine Omega-3 Fatty Acids and Cardiovascular Disease , 2011 .

[8]  M. Ueeda,et al.  High Plasma Docosahexaenoic Acid Associated to Better Prognoses of Patients with Acute Decompensated Heart Failure with Preserved Ejection Fraction , 2021, Nutrients.

[9]  J. O’Keefe,et al.  An Update on Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Health , 2021, Nutrients.

[10]  C. Patrono,et al.  The REDUCE-IT verdict on eicosapentaenoic acid and cardiovascular outcome challenged with STRENGTH. , 2020, European heart journal.

[11]  F. Visioli,et al.  Fatty Acids and Cardiovascular Risk. Evidence, Lack of Evidence, and Diligence , 2020, Nutrients.

[12]  D. Mozaffarian,et al.  Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. , 2020, JAMA.

[13]  G. Curfman.  Do Omega-3 Fatty Acids Benefit Health? , 2020, JAMA.

[14]  R. Blumenthal,et al.  Effects of Omega-3 Fatty Acids on Major Adverse Cardiovascular Events: What Matters Most: the Drug, the Dose, or the Placebo? , 2020, JAMA.

[15]  Deepak L. Bhatt,et al.  A Revolution in Omega-3 Fatty Acid Research. , 2020, Journal of the American College of Cardiology.

[16]  I. Komuro,et al.  Omega-3 fatty acid prevents the development of heart failure by changing fatty acid composition in the heart , 2020, Scientific Reports.

[17]  Deepak L. Bhatt,et al.  Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction. , 2020, Future cardiology.

[18]  C. Lavie,et al.  Effect of Omega-3 Dosage on Cardiovascular Outcomes: An Updated Meta-Analysis and Meta-Regression of Interventional Trials. , 2020, Mayo Clinic proceedings.

[19]  Deepak L. Bhatt,et al.  Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial , 2020, European heart journal.

[20]  R. Sethi,et al.  Triglycerides and Cardiovascular Outcomes—Can We REDUCE-IT ? , 2020, International Journal of Angiology.

[21]  I. Tatsuno,et al.  Prevention of Cardiovascular Events with Omega-3 Polyunsaturated Fatty Acids and the Mechanism Involved , 2020, Journal of atherosclerosis and thrombosis.

[22]  K. Reynolds,et al.  Increased Cardiovascular Risk in Hypertriglyceridemic Patients With Statin-Controlled LDL Cholesterol , 2018, The Journal of clinical endocrinology and metabolism.

[23]  I. Tatsuno,et al.  Omega-3 polyunsaturated fatty acids for cardiovascular diseases: present, past and future , 2017, Expert review of clinical pharmacology.

[24]  D. Hilleman,et al.  The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia , 2016, Lipids in Health and Disease.

[25]  I. Tatsuno,et al.  Effect of TAK‐085 on Low‐density Lipoprotein Particle Size in Patients with Hypertriglyceridemia: A Double‐blind Randomized Clinical Study , 2015, Cardiovascular therapeutics.

[26]  K. Yamagishi,et al.  Fasting and non-fasting triglycerides and risk of ischemic cardiovascular disease in Japanese men and women: the Circulatory Risk in Communities Study (CIRCS). , 2014, Atherosclerosis.

[27]  P. Austin.  The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments , 2013, Statistics in medicine.

[28]  I. Tatsuno,et al.  Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized long-term (ORL) study. , 2013, Journal of clinical lipidology.

[29]  I. Tatsuno,et al.  Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized double-blind (ORD) study. , 2013, Journal of clinical lipidology.

[30]  U. Sampson,et al.  Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges , 2012, Current Atherosclerosis Reports.

[31]  Y. Kokubo,et al.  A revised definition of the metabolic syndrome predicts coronary artery disease and ischemic stroke after adjusting for low density lipoprotein cholesterol in a 13-year cohort study of Japanese: the Suita study. , 2011, Atherosclerosis.

[32]  M. Inoue,et al.  The impact of the metabolic syndrome and its components on the incidence of ischemic heart disease and stroke: the Japan public health center-based study , 2009, Hypertension Research.

[33]  L. Kuller,et al.  Marine-derived n-3 fatty acids and atherosclerosis in Japanese, Japanese-American, and white men: a cross-sectional study. , 2008, Journal of the American College of Cardiology.

[34]  H. Ueshima,et al.  Differences in cardiovascular disease risk factors between Japanese in Japan and Japanese-Americans in Hawaii: the INTERLIPID study , 2003, Journal of Human Hypertension.